Post Operative Shivering Following Anesthesia

Pharmacological Management of Post Operative Shivering Following Anesthesia

Status

Not yet recruiting

Phases

Unknown

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT07377903

Enrollment

Registered

2026-01-30

Start date

2026-02-01

Completion date

2026-09-01

Last updated

2026-02-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Shivering, Spinal Anesthesia

Brief summary

The aim of this study is to compare the efficacy of magnesium sulphate, ondansetron, and dexmedetomidine in managing post-spinal anesthesia shivering. The primary aim is the time to cessation of shivering after drug administration, while secondary aim include hemodynamic parameters (heart rate, blood pressure, SpO₂ ) and the recurrence of shivering

Detailed description

This is a randomized double blinded study including patients undergoing surgery under spinal anesthesia. Patients will be randomly allocated into three groups to receive magnesium sulphate, ondansetron, or dexmedetomidine for the treatment of post-spinal anesthesia shivering. The time to cessation of shivering, hemodynamic parameters, and recurrence of shivering will be recorded.

Interventions

DRUGDexmedetomidin

•Group D (Dexmedetomidine Group): 0.5 µg/kg dexmedetomidine diluted in 100 mL of normal saline.

DRUGMg (magnesium sulfate)

50 mg/kg magnesium sulphate diluted in 100 mL of normal saline.

DRUGOndansetron 8 mg

8 mg ondansetron diluted in 100 mL of normal saline.

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to 45 Years

Healthy volunteers

Yes

Inclusion criteria

* Age from 18 to 45 years. * Both sexes. * American Society of Anesthesiologists physical status I, II * Scheduled for elective lower abdominal or lower limb surgeries under spinal anesthesia

Exclusion criteria

* Patients with known allergy to study drugs. * Patients with baseline body temperature outside the normal range (36-37.5°C). * History of thermoregulatory disorders, thyroid dysfunction, or neurological diseases. * Patients receive sedatives, antipsychotics, or antidepressants. * Patients require intraoperative conversion to general anesthesia.

Design outcomes

Primary

Measure	Time frame	Description
Time to cessation of shivering after drug administration.	6 hours	Grade 0: No shivering. * Grade 1: Piloerection or peripheral vasoconstriction but no visible shivering. 4 * Grade 2: Muscular activity in only one muscle group. * Grade 3: Muscular activity in more than one muscle group. * Grade 4: Whole-body shivering.

Contacts

CONTACTAya Mohammed Aboelwafa, Resident of anesthesia

aya_muhammad_post@med.sohag.edu.eg01095848062

CONTACTAhmed Elsaied Abd Elrahman, Professor

elsaiedsoon@gmail.com01118011611

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026